Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Increases By 28.5%

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 8,510,000 shares, an increase of 28.5% from the January 31st total of 6,620,000 shares. Based on an average daily volume of 13,950,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 11.2% of the shares of the company are short sold.

Insider Activity

In other news, Director Terrance Mcguire sold 150,000 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the sale, the director now directly owns 4,538,079 shares of the company’s stock, valued at $2,768,228.19. This trade represents a 3.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 816,466 shares of company stock valued at $423,214 in the last ninety days. 17.90% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

Large investors have recently modified their holdings of the business. State Street Corp boosted its position in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Barclays PLC boosted its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after acquiring an additional 75,780 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Invivyd during the 3rd quarter valued at about $27,000. Two Sigma Investments LP boosted its position in shares of Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after acquiring an additional 204,188 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Price Performance

IVVD stock traded up $0.11 during mid-day trading on Tuesday, reaching $1.05. 10,577,105 shares of the company traded hands, compared to its average volume of 21,932,908. The company has a market capitalization of $125.60 million, a P/E ratio of -0.54 and a beta of 0.61. Invivyd has a 52-week low of $0.35 and a 52-week high of $4.74. The company has a fifty day moving average price of $0.89 and a 200-day moving average price of $0.87.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Monday, February 24th. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Monday, February 24th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Invivyd presently has an average rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.